David Shaw’s BioMarin Pharmaceuticals BMRN Stock Holding History

David Shaw’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$1.75M	–	4059
2020 Q4	$1.75M	Hold	20,000	–	–	﹤0.01%	2641
2020 Q3	$1.52M	Sell	20,000 -400	-2%	-$40.5K	﹤0.01%	2575
2020 Q2	$2.52M	Buy	20,400 +400	+2%	+$39.8K	﹤0.01%	2219
2020 Q1	$1.69M	Hold	20,000	–	–	﹤0.01%	2315
2019 Q4	$1.69M	Hold	20,000	–	–	﹤0.01%	2611
2019 Q3	$1.35M	Hold	20,000	–	–	﹤0.01%	2652
2019 Q2	$1.71M	Buy	+20,000	New	+$1.71M	﹤0.01%	2338
2019 Q1	–	Sell	-10,000	Closed	-$852K	–	3598
2018 Q4	$852K	Hold	10,000	–	–	﹤0.01%	2770
2018 Q3	$970K	Hold	10,000	–	–	﹤0.01%	2719
2018 Q2	$942K	Hold	10,000	–	–	﹤0.01%	2734
2018 Q1	$811K	Sell	10,000 -38,000	-79%	-$3.26M	﹤0.01%	2627
2017 Q4	$4.28M	Hold	48,000	–	–	0.01%	1601
2017 Q3	$4.47M	Hold	48,000	–	–	0.01%	1458
2017 Q2	$4.36M	Hold	48,000	–	–	0.01%	1450
2017 Q1	$4.21M	Sell	48,000 -60,000	-56%	-$5.34M	0.01%	1394
2016 Q4	$8.95M	Hold	108,000	–	–	0.02%	1008
2016 Q3	$9.99M	Buy	108,000 +18,000	+20%	+$1.69M	0.02%	889
2016 Q2	$7M	Hold	90,000	–	–	0.01%	1086
2016 Q1	$7.42M	Hold	90,000	–	–	0.01%	1024
2015 Q4	$9.43M	Buy	90,000 +10,000	+13%	+$1.04M	0.01%	996
2015 Q3	$8.43M	Buy	80,000 +20,000	+33%	+$2.67M	0.01%	1064
2015 Q2	$8.21M	Buy	60,000 +30,000	+100%	+$3.72M	0.01%	1131
2015 Q1	$3.74M	Buy	30,000 +20,000	+200%	+$2.12M	0.01%	1568
2014 Q4	$904K	Hold	10,000	–	–	﹤0.01%	2905
2014 Q3	$722K	Hold	10,000	–	–	﹤0.01%	3071
2014 Q2	$622K	Hold	10,000	–	–	﹤0.01%	3342
2014 Q1	$682K	Buy	+10,000	New	+$737K	﹤0.01%	3348

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

David Shaw's BMRN Position: Q2 2026 in Review

David Shaw reduced its BioMarin Pharmaceuticals (BMRN) stake by 67% in Q2 2026, selling an estimated $10.4M and leaving 92,214 shares worth $5.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

David Shaw first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $146M in Q4 2022. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

David Shaw held 92,214 shares of BioMarin Pharmaceuticals worth $5.28M as of Q2 2026.
David Shaw sold 190,246 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $10.4M.
BioMarin Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2356 holding.
David Shaw first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
David Shaw's BioMarin Pharmaceuticals position peaked at $146M in Q4 2022.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.